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 Scleroderma as an immune fibrotic disorder 
Systemic sclerosis (scleroderma, SSc) is a connective tissue disease in which a dysregulated immune 
process in the involved tissues is linked to persistent myofibroblast activation, resulting in skin and 
organ fibrosis of varying severity (Allanore et al., 2015).  Current concepts indicate that the disease 
onset is triggered by environmental factors in individuals predisposed by genetic polymorphisms in 
immune-regulatory genes (Mayes et al., 2014).  Immune cells, including macrophages, mast cells, as 
well as T helper cells, are recruited into the skin lesions at an early stage of the disease (Fleischmajer 
et al., 1977, Roumm et al., 1984, Hawkins et al., 1985).  It is believed that the aberrant local immune 
response involving T helper cells and alternatively activated macrophages contribute to the pro-
fibrotic microenvironment (Wermuth and Jimenez, 2015, O'Reilly et al., 2012).  Local resident 
fibroblasts are activated to become myofibroblasts and other myofibroblast precursor cells derived 
from circulating monocytes (fibrocytes) as well as cells undergoing EndoMT and possibly EMT are 
drawn into the fibrotic lesions(Postlethwaite et al., 2004, Nikitorowicz-Buniak et al., 2015, Good et 
al., 2015, Mathai et al., 2010).  Mechanical stress in the extracellular matrix, autocrine stimulation 
and epigenetic changes result in persistence of myofibroblasts through failure of apoptosis and 
ongoing extracellular matrix (ECM) overproduction (Shiwen et al., 2015, Altorok et al., 2014).  
Current strategies to treat this condition include immunosuppression or specific targeting of 
pathogenic cytokines and growth factors, but none of these approaches are curative and all have 
undesirable off-target effects (Khanna et al., 2016a, Lafyatis, 2014, Tashkin et al., 2016).  Autologous 
stem cell therapy may achieve remission in some patients but has a 10% risk of mortality in the first 
year after treatment (van Laar et al., 2015).   It is possible that improved understanding of the 
factors recruiting immune and fibrotic cells into the lesions could lead to more specific therapies 
with fewer off-target effects.  Furthermore, the local production of chemo-attractants in the fibrotic 
lesions could be manipulated to recruit cell based therapies into the lesions (Vignali and Kallikourdis, 
2017) (http://fibrocell.com/pipeline-clinical-trials/fcx-013-gene-therapy-for-linear-scleroderma).  
 
Chemokine background 
Chemokines are small proteins of 8-10 kDa having two cysteine residues in conserved sites in the N 
terminus(Le et al., 2004, Arimont et al., 2017).  The conformation of the cysteine residues has been 
used to classify these proteins as CC, having adjacent cysteine residues and typically involved in 
macrophage and T cell recruitment, CXC having an intervening amino acid between cysteines and 
typically involved in neutrophil recruitment, as well as CX3C which has 3 interposed amino acids and 
comprises a single member, fraktalkine.  Furthermore, the C subtype has a single cysteine residue 
and includes lymphotactin-α and β.  In general chemokines function as soluble factors which recruit 
innate and adaptive immune cells into sites of injury or pathogen invasion, acting via seven 
transmembrane receptors coupled to heterotrimeric G proteins which signal via phospholipase C 
and alter migration through elevation of  intracellular calcium (Kufareva, 2016).  The chemokine-
chemokine receptor system has a high degree of redundancy so that multiple chemokines can act at 
each receptor.  Overall this leads to a highly complex network of chemokine related pathways 
including at least 28 CCL proteins, 17 CXCL ligands each with overlapping effects on receptors CCRs 
1-10 and CXCRs 1-6 as well as the fraktalkine receptor CX3CR1.   
Furthermore, other secreted proteins can act as important chemo-attractants involved in the 
response to tissue injury leading to optimal tissue repair, but induced in pathologic conditions, 
including PDGF, which recruits myofibroblast precursors into wounds and fibrotic lesions(Seppa et 
al., 1982), as well as stem cell factor (SCF)(Yamamoto et al., 2001), an attractant for c-kit positive 
mast cells and progenitor cells,  plus stromal cell-derived factor 1 (CXCL12) implicated in recruitment 
of fibrocytes into lesions(Seppa et al., 1982, Bucala et al., 1994, Tourkina et al., 2011).  As discussed 
below it is likely that chemokines and these other chemo-attractants are involved at multiple steps 
in the scleroderma disease process, following some disease initiating insult leading to their 
expression in the damaged tissues. It is possible that therapeutics targeting the chemokines could be 
of benefit overall in scleroderma, or in pathogenic subgroups of the disease.  Limitations include the 
multiple chemokines and chemoattractants involved and the molecular promiscuity of the 
chemokine receptors. 
Initiation of tissue injury in scleroderma 
Scleroderma onset is linked to occupational exposure including exposure to organic solvents such as 
trichloroethylene, working with polyvinyl chloride, and silica dust exposure (Stephens et al., 1994, 
Englert et al., 2005, Marie and Gehanno, 2015).  Furthermore certain geographical clusters have 
been described in keeping with an environmental initiating factor.  Concordance between siblings or 
first degree relatives is often near-synchronous, implicating some common environmental exposure 
(Arnett et al., 2001, Feghali-Bostwick et al., 2003). As with most complex autoimmune disorder,s 
viral exposures have also been implicated in triggering the onset of the disease, and we have 
experience of patients triggered by proven acute CMV infection for example (Goulabchand et al., 
2014, Arnson et al., 2009).  Damage to and activation of environment-exposed integument cell 
layers including epithelial and endothelial cells is seen at early stage in SSc (Aden et al., 2008, Aden 
et al., 2010, Kahaleh and LeRoy, 1999).  Multiple studies indicate that microvascular endothelial cell 
damage is present at clinical onset in the majority of cases(Saito and Ishikawa, 1976, Freemont et al., 
1992).  Microvascular endothelial cell apoptosis, adhesion molecule expression and elevated 
reactive oxygen species (ROS) production are all seen, leading to enhanced adhesion and migration 
of circuating immune cells (Gabrielli et al., 2009, Svegliati et al., 2014, Kuwana et al., 2004, Denton et 
al., 1995).  Recruitment of immune cells into the dermis or affected organs is likely to be driven by 
local overproduction of chemokines and a gradient between the involved tissues and circulating 
plasma.   
Chemokines induced in the disease microenvironment in early and late stage disease 
Monocyte chemoattractant proteins (MCP) are a subfamily within the CC chemokines strongly 
implicated in scleroderma. MCP-1 (CCL2) was first identified as a monocyte-specific chemoattractant 
secreted by glioma cells (Yoshimura et al., 1989).  Overexpression of MCP-1 by scleroderma skin 
fibroblasts was first shown to induce migration of macrophages across an endothelial monolayer 
towards scleroderma fibroblasts overproducing the chemokine, and furthermore elevated MCP-1 in 
scleroderma tissues has been demonstrated in multiple studies (Denton et al., 1998, Matsushita et 
al., 2006, Hasegawa et al., 2011).  In these analyses it was shown that multiple cell types within the 
lesions are responsible for production of MCP-1, including fibroblasts, endothelial cells, 
keratinocytes as well as mononuclear cells.  The mechanistic importance of these findings is 
supported by demonstration of co-localisation of macrophages expressing CCR2, the receptor for 
MCP-1, with the cells expressing the chemokine in scleroderma tissues (Carulli et al., 2005).   
Furthermore scleroderma fibroblasts continue to overexpress CCR2 in tissue culture, and induce 
MCP-1 following stimulation by IFNγ plus TNFα. Strong elevation of MCP-1 correlates with the more 
severe diffuse cutaneous disease subset as well as with the development of pulmonary fibrosis, 
indicating a role in the development of major fibrotic features (Carulli et al., 2008). Furthermore 
MCP-1 has a role in Th2 polarisation consistent with a pro-fibrotic mechanism (Karpus et al 1997). 
There are four further members of the MCP family which have a high degree of homology between 
family members, of which MCP-3 (CCL7) has been studied in scleroderma (Ong et al., 2003, Yanaba 
et al., 2006, Distler et al., 2009).  MCP-3 binds to the same receptor as MCP-1, CCR2, but is also a 
ligand at CCR1 and 3.  In scleroderma tissues MCP-3 is overexpressed by basal layer keratinocytes, 
dermal fibroblasts as well as mononuclear cells.   MCP-3 has been shown in systematic studies to be 
overproduced in scleroderma lesions and is believed to promote monocyte and T cell recruitment, 
and to be a direct stimulant to fibroblasts leading to collagen I induction (Ong et al., 2003).  MCP-3 is 
implicated in mouse models of fibrosis and is induced in fibroblasts by the pro-fibrotic growth factor 
TGFβ.    
Furthermore, other chemokines have been shown to be elevated in the disease tissue, including 
RANTES, MIP-1α, MIP-1β as well as fractalkine and IP10, and the data are summarized in Table 1  
(Hasegawa et al., 2005, Rabquer et al., 2011, Bandinelli et al., 2012, Corrado, 2014). 
RANTES (CCL-5) interacts with CCR1, CCR3 and CCR5, and is chemotactic for T-cells, eosinophils and 
basophils (Schall et al., 1988). MIP-1α (CCL-3) and MIP-1β (CCL-4) are structurally similar chemokines 
produced by many cells, particularly macrophages, dendritic cells and lymphocytes (Sherry et al., 
1988). MIP-1α interacts with CCR1, CCR4, and CCR5, whereas MIP-1β shows specificity for CCR5. 
Both MIP factors are involved in the recruitment and activation of many pro-inflammatory cells, 
including polymorphonuclear cells, as well as CD4 and CD8 T-cells. MIP-1α and MIP-1β are 
considered important chemo-attractants for activated T cells.  This was demonstrated in tissue 
culture where recombinant MIP-1 proteins only attracted T cells which had been activated by 
monoclonal antibody to CD3. In fact recombinant MIP-1β attracted CD4+ T helper subset whereas 
recombinant MIP-1α attracted predominantly CD8+ T lymphocytes. Furthermore, these factors 
increased T cell adhesion to endothelial cells in tissue culture (Taub et al., 1993).  
Elevated serum levels of RANTES, MIP-1α and MIP-1β has been observed in scleroderma patients 
compared to controls (Bandinelli et al., 2012, Hasegawa et al., 2013) and increased production of 
MIP-1α and MIP-β by peripheral blood derived monocytes has been demonstrated  (Hasegawa et al., 
2013). Furthermore, increased cutaneous expression of RANTES and MIP-1α mRNA precedes skin 
thickening in a murine model of scleroderma (Zhang et al., 2002), with RANTES showing greatest 
early increase in expression and then falling more rapidly compared to MIP-1α. 
 Presence of these chemokines has also been demonstrated in tissues of organ affected in 
scleroderma. Increased levels of RANTES and MIP-1α have been detected in the bronchoalveolar 
lavage (BAL) fluid of scleroderma patients (Bolster et al., 1997). In this study, BAL fluid 
concentrations of MIP-1α were significantly higher in scleroderma patients with alveolitis compared 
to those without alveolitis and compared to healthy controls, whereas BAL fluid concentrations of 
RANTES were significantly higher only in scleroderma patients without alveolitis compared to 
healthy controls. Furthermore, abundant expression of RANTES mRNA has been observed in the skin 
of scleroderma patients, with no expression seen in healthy controls in the same study (Anderegg et 
al., 2000). 
In one study MCP-1 was found to correlate with Modified Rodnan Skin Score (Bandinelli et al., 2012), 
whereas RANTES and MIP-1α failed to correlate with diffuse or limited subgroups.  The overall 
abundance of MIP-1α was very low relative to RANTES and MCP-1. 
Role of fractalkine: a unique class of chemokine which can be membrane bound or soluble 
In 1997 Bazan reported a unique chemokine with CX3C structure, with unique tissue distribution, 
termed fractalkine/CX3CL1 (Bazan et al., 1997).  Fractalkine is synthesized as a transmembrane 
molecule consisting the extracellular domain and a mucin-like stalk which can be cleaved from the 
cell surface by metalloproteinases ADAM17 and ADAM10, and so can act both as an adhesion 
molecule and soluble chemoattractant (Bourd-Boittin et al., 2009).  Fractalkine acts as a 
chemoattractant for monocytes, NK cells and T cells(Imai et al., 1997). Membrane bound fractalkine 
can be induced on endothelial cells by inflammatory cytokines.  
Fractalkine has been studied in scleroderma by Hasegawa et al 2005, showing enhanced expression 
in the skin and lungs of patients.  This increased expression augments the recruitment of 
mononuclear cells into the affected tissue leading to inflammation (Hasegawa et al., 
2005)(Hasegawa et al., 2005). Polymorphisms of the fractalkine receptor CX3CR1 are associated with 
susceptibility to scleroderma and scleroderma related complications (Marasini et al., 2005).  The 
429I and 480M alleles are associated with the development of pulmonary hypertension in 
scleroderma, whereas overall increased susceptibility is associated with the 249II polymorphism 
(Marasini et al 2005).  Furthermore use of prostanoid infusions, which are a therapeutic for vascular 
manifestations, were found to reduce serum fractalkine levels in scleroderma patients (Sicinska et al 
2008).   
 
Chemokines can also regulate angiogenesis 
Chemokines, in addition to their immune chemoattractant properties, can act as regulators of 
angiogenesis, a process which is significantly dysregulated in scleroderma (Kahaleh and LeRoy, 
1999). Chemokines acting as inhibitors of angiogenesis include monokine induced by interferon-γ 
(IFN-γ) (MIG/CXCL9) and IFN-inducible protein 10 (IP-10/CXCL10).  These factors inhibit angiogenesis 
through binding to CXCR3, whereas CXCL16 is believed to be pro-angiogenic acting through CXCR6.  
This system has been studied in scleroderma by Rabquer and colleagues, indicating that the anti-
angiogenic factors IP-10 and MIG were elevated in serum of patients (Rabquer et al., 2011).  A 
complex picture emerged from these studies indicating that IP-10 and MIG/CXCL9 were elevated but 
the CXCR3 receptor is decreased.  Furthermore, the pro-angiogenic CXCL16 is overexpressed as is its 
receptor in the scleroderma endothelial cells.  These findings support a model of vascular injury and 
dysregulated repair in scleroderma and parallel the findings with VEGF which is increased in the 
disease but fails to restore vascular integrity.  These aberrant vascular repair mechanisms may 
explain chaotic vascular lesions seen in patients such as skin telangiectasia and gastric antral vascular 
ectasia (GAVE).  
Many studies suggest that the IP-10/CXCR3 axis has a role in autoimmune conditions and in fibrosis 
in patients with scleroderma. A longitudinal study of IP10 plus MCP-1 have shown high levels of both 
chemokines in recent onset scleroderma.  Subsequently IP-10 declined during follow up whereas the 
MCP-1 levels remained high.  Furthermore, high baseline IP-10 correlated with severe clinical 
involvement such as pulmonary and renal involvement.  One possible interpretation of these data is 
that IP10 is being released by Th1 cells in severe early disease, which switch to a Th2 response in 
ongoing later stages of disease, indicating an inflammatory initiation phase and pro-fibrotic 
downstream phase.  Other studies have shown that IP-10 is a marker of a more aggressive 
autoimmune process involving organs such as thyroid or lung. Fibroblasts from scleroderma patients 
overproduce IP10 which can be induced further by IFNs. Furthermore, it has been suggested that the 
IFN-inducible chemokine IP-10 is a stable serologic marker of a more severe form of scleroderma 
and may be useful for risk stratification of patients, regardless of disease type (limited or diffuse). 
 
Multiplex analysis of chemokines in tissue fluid: chemokine levels in early and late stage disease 
In our own studies we have used dermal suction blister fluid sampling as a minimally invasive 
method to gain insight into the levels of soluble chemokines present in the disease 
microenvironment.  These samples can be analysed by Luminex Multiplex analysis, or by further 
technologies which are expanding in the capacity for analysis of multiple factors.  When unbiased 
hierarchical clustering was applied patients and chemokines were found to cluster into groups.  The 
patients were found to cluster into 3 clinically distinct groups; firstly a group with relatively early 
diffuse scleroderma (mean disease duration 5 years, skin score 27), secondly a late stage diffuse 
scleroderma group (late stage disease duration 14 years, skin score 21), and thirdly a group with 
limited or mild diffuse with bland expression of chemokines and growth factors (mean disease 
duration 7.5 years, skin score 10).  The heat-map is shown in Figure 1.  Based on this analysis a 
cluster of chemokine expression in early disease was seen indicating high levels of MCP-1, 
fractalkine, RANTES and MIP-1α and 1β which co-clustered with innate inflammatory cytokines such 
as TNFα, IL-6 and IL-1α.  In the late stage diffuse group MCP-3 and IP-10 were elevated and co-
clustered with Th2 cytokines IL-4, 5 and 13. Limitations of the study are the small number of patients 
included who were untreated and in the very earliest stages. 
The question of an early versus late role of these chemokines  in fibrosis has been addressed in 
mouse models of scleroderma.  In these studies MCP-1, RANTES, and MIP-1α were all elevated in 
early stages of the fibrotic model, with RANTES having the earliest role, whereas MCP-1 and MIP-1α 
persisted while RANTES declined rapidly (Uguccioni et al 1995).   
Studies from Japan have assessed the expression levels of chemokines longitudinally in scleroderma 
patients.  In one study annual plasma samples were assayed for 3 years, measuring IP-10, MIG 
(CXCL9), IL-8 and correlation sought with clinical parameters.  IP10, MIG and IL-8 were significantly 
elevated in scleroderma versus controls. MCP-1 correlated with skin score and lung involvement as 
assessed by MRSS and FVC, indicating that MCP-1 was the most useful biomarker (Hasegawa et al., 
2011).  In one further longitudinal study levels of these chemokines plus RANTES, were examined in 
scleroderma patients, where annual blood samples were assayed longitudinally over a four year 
period and compared to outcome including disability index HAQ-DI.  Of the chemokines studied 
baseline CXCL8 (IL-8) levels correlated with HAQ-DI at year 4 (Hasegawa et al., 2013).  
Role of atypical chemokine receptor D6 in scleroderma 
More recent evidence has indicated an atypical family of chemokine receptors which fail to signal 
and act as an anti-inflammatory regulatory mechanism binding excess chemokines present in the 
extracellular environment.  Such receptors would be of therapeutic interest, since they bind multiple 
agonists and could be manipulation to reduce chemokine levels in disease.  D6 is one such  
'scavenging' receptor, which binds CC chemokines and is thereof reo fin interest in systemic 
sclerosis.  An interesting study from Glasgow examined D6 expression levels in peripheral blood 
mononuclear cells in scleroderma, and attempted to distinguish between D6 high expressing and 
low expressing individuals (Codullo et al., 2011).  D6 was found to be 10 fold elevated in scleroderma 
peripheral blood mononuclear cells.  Also, these studies confirmed elevation of MCP-1, IL-8, MIP-
1α&β.  In general inflammatory cytokine levels did not differ between D6 high and low groups, 
however MIP-1α levels were lower in D6 high patients consistent with absorption/neutralization by 
D6.  
Chemokines in scleroderma: implications for therapy 
In recent years development of specific biologic therapies has enabled clinical trials in scleroderma 
which not only inform potential therapies but also give the clearest experiment to test the 
importance of the growth factors or cytokines targeted (Khanna et al., 2016b, Rice et al., 2015).  In 
this phase it might be possible to evaluate specific therapies blocking chemokines or 
chemoattractants in order to test efficacy and determine the overall importance of the chemokine 
or chemokine receptor involved.  
Because of their implication in multiple immune and inflammatory conditions a very large of number 
of therapeutics targeting chemokines or their receptors have been developed.  Examples include an 
MCP-1 mimetic which blocks the effect MCP-1 at CCR2, as well as orally active CCR2 signalling 
inhibitors which have been shown to inhibit monocyte recruitment in mouse models. Monoclonals 
against MCP-1 led to the unpredicted greatly elevated plasma levels of MCP-1 and worsening 
systemic inflammation.  
Antagonism of the protein-protein interactions between chemokines their receptors by small 
molecules are considered challenging.  However G-protein coupled receptors such as the chemokine 
receptors are drugable targets, and multiple small molecule inhibitors have been developed.   
Furthermore, elucidation of the 3-D structure of the chemokine receptors has enabled effective 
inhibitors to be developed, leading to a large range of potential therapeutics.  Of note in 
scleroderma CCR2 antagonists are available (INCB3284 Incyte, BMS-741672 Bristol-Meyers 
Squibb BMS-741672Bindarit Angelini Bristol-Meyers Squibb, JNJ-17166864 Johnson & 
Johnson) as well as antagonists of MCP-1, although none of these drugs has reached the clinical 
market. Clinical failure has been for a variety of reasons but further drug development is ongoing.   A 
CCR2 antagonist, CCX-140, is in a Phase3 trial for Type 2 diabetes with diabetic nephropathy  
(Hanefeld et al., 2012; Sullivan et al., 2013) and also a CCR9 antagonist CCX282 is in Phase 2 trials for 
inflammatory bowel disease  (Keshav et al., 2013).  Furthermore the CCR1 inhibitor CCX354, has 
completed a Phase 2 trial for rheumatoid arthritis being well tolerated and exhibiting possible 
efficacy at higher dose  (Tak et al., 2013).  Furthermore, FX-125L is an orally-active small molecule 
developed by Funxional Therapeutics, described as a somatotaxin  acting through the type-2 
somatostatin receptor and currently being evaluated by Boehringer Ingelheim as a treatment 
for COPD, asthma and rheumatoid arthritis. 
Chemokine receptor antagonist nanobodies have also shown efficacy in pre-clinical models, 
broadening the repertoire of therapeutic approaches (Maussang et al., 2013).   
Through these multiple potential strategies it might be possible to inhibit cellular recruitment into 
the immune-fibrotic disease microenvironment in scleroderma patients (Figure 3).  Furthermore, it 
should be possible to individualise tailor-made therapy based on the individual chemokine 
environment.   We propose that the dermal blister fluid profiling method will be a key part of these 
treatment approaches, enabling tailor made therapy.  Repeat sampling after chemokine inhibitor 
therapy could be used to demonstrate biologic effect and or silencing of the specific target.  
Conclusions and future perspectives 
Chemokines and their cognate receptors are important modulators of scleroderma.  In particular their 
altered expression, inappropriate activation and utilization are likely to plan important roles at all 
stages of the disease process including the early vasculopathy, developing inflammatory phase leading 
to autoimmunity, and the late stage of established scarring and fibrosis (Figure 3).  These molecules 
and their receptors have therefore in the last decade become highly attractive targets for multiple 
therapeutic approaches (Proudfoot, 2002, Horuk, 2009, O’Hayre et al., 2010, Klarenbeek et al., 2012, 
Blanchetot et al., 2013, Rees et al., 2015).  The development of antibodies, antagonists and chemokine 
binding proteins have all advanced the field, but have also highlighted the challenges including 
chemokine and receptor redundancy, correct target selection, differential expression and diversity 
(Klarenbeek et al. 2012).  Effective application of chemokine/receptor therapies in scleroderma will 
require a more thorough understanding of the complex interactions and involvement of these factors 
in pathogenesis. This will no doubt require the use of these sophisticated therapies within disease 
endotypes, targeting perhaps multiple or sequential chemokine/receptor pathways along the natural 
history of the disease. Nonetheless, and despite these clear hurdles, chemokines and their receptors 









Cellular origin Target cells Putative role in scleroderma Early versus late  Therapeutic antagonist 
MCP1 (CCL2) CCR2 Fibroblasts, endothelium, 
keratinocytes, 
monocytes. 
T cells and Monocytes Correlation with severity of 
skin and lung fibrosis 
Early and then 
maintained 
CCR2 antagonists 




T cells and Monocytes Recruitment of immune cells 
in early disease 
Early  
Fracktalkine CX3CR Activated endothelium Adhesion/recruitment 
of monocytes, NK cells 
and T cells 
Pulmonary hypertension risk 
via SNPs 
Early  
IP10  Monocytes, endothelium, 
fibroblasts 
 Severe disease biomarker Early then declining  
RANTES CCR1,3&
5 
T cells T cells, mast cells, 
eosinophils 
Cellular recruitment into 
lungs 





Macrophages Activated CD8+ T cells  Very early (mouse 
models) 
 
MIP1β CCR5 Macrophages Activated CD4+ T cells    
SCF c-Kit Keratinocytes, scleroderma 
fibroblasts 
Mast cells,  stem cells Recruitment of mast cells and 
progenitor cells  




CCR4  Fibrocytes Recruitment of fibrocytes 
into areas of lung fibrosis 
Not known  
PDGF PDGFR1-
4 
Platelets, macrophages Fibroblasts, fibroblast 
precursors 
Recruitment of fibroblasts 
and fibroblast precursors. 
Not known Tyrosine kinase 
inhibitors 
Table 1 Summary of the role of chemokines and other chemoattractants in scleroderma
 Figure 1 Heirarchial clustering of chemokines cytokines and growth factors in scleroderma.  
Patients clustered in 3 groups; Group 1 with earl stage diffuse scleroderma, group 2 with late stage 
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